3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
9
Carcinoma, Transitional Cell
4
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Ureteral Neoplasms
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Interventions
Dexamethasone
4
pomalidomide
2
Azacitidine
2
vinflunine
1
trifluridine tipiracil drug combination
1
trebananib
1
safinamide
1
sacubitril and valsartan sodium hydrate drug combination
1
rubitecan
1
ripretinib
1
regorafenib
1
pevonedistat
1
pembrolizumab
1
osimertinib
1
mirabegron
1
melflufen
1
gallium 68 PSMA-11
1
copanlisib
1
carfilzomib
1
belinostat
1
belantamab mafodotin
1
Zoledronic Acid
1
Topotecan
1
Tablets
1
Sitagliptin Phosphate
1
Pluvicto
1
Paclitaxel
1
Lenalidomide
1
L-melphalanyl-p-L-fluorophenylalanine ethyl ester
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Renal Insufficiency
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled